Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Seliciclib - Cyclacel Pharmaceuticals

Drug Profile

Seliciclib - Cyclacel Pharmaceuticals

Alternative Names: CYC 202; R-roscovitine; Seliciclib

Latest Information Update: 21 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cyclacel Pharmaceuticals
  • Developer Cedars-Sinai Health System; Cyclacel Pharmaceuticals; University Hospital, Brest; University of Newcastle upon Tyne
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cell cycle protein inhibitors; Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase-activating kinase inhibitors; MCL1 protein inhibitors; MCL1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cushing syndrome; Cystic fibrosis; Nasopharyngeal cancer; Non-small cell lung cancer; Pituitary ACTH hypersecretion; Rheumatoid arthritis
  • Phase I Solid tumours
  • No development reported Breast cancer
  • Discontinued Glomerulonephritis; Haematological malignancies

Most Recent Events

  • 17 Dec 2018 3364521 - update only: updated KDM and PD section , profile already reviewed
  • 17 Dec 2018 Pharmacodynamics data from a preclinical trial in Glioblastoma presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2018 (3364521)
  • 22 Nov 2018 National Institute of Diabetes and Digestive and Kidney Diseases terminates a phase II trial in Cushing's disease (Pituitary ACTH hypersecretion) in USA, since the NIH grant ended (NCT02160730)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top